Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2025-04-22 Notice of Dividend Amou…
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
2024年年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is a detailed announcement regarding the company's 2024 annual equity distribution plan, including cash dividend proposals, board and supervisory committee approvals, and references to the company's profit distribution policies and related corporate governance rules. It discusses the dividend amount, share repurchases, and the decision-making process for profit distribution. The document is not the full annual report but specifically focuses on the dividend distribution plan and related corporate governance and procedural details. It is not a simple announcement of a report publication but a substantive disclosure about dividend plans and related corporate actions. This fits the definition of a Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2025-04-22 Chinese
第七届监事会第二十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of various proposals including the 2024 Supervisory Board Work Report, 2024 Annual Report and Summary, 2024 Financial Final Report, 2025 Financial Budget Report, and other related reports. The document references that the actual reports (Annual Report, Financial Report, etc.) are disclosed separately on the Beijing Stock Exchange information disclosure platform with specific announcement numbers. The document itself does not contain the full annual report or financial statements but is a formal announcement of the Supervisory Board meeting resolutions approving these reports and proposals, which will be submitted to the shareholders' meeting for further approval. The document length is 3693 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the MENU VS MEAL RULE and the nature of the content, this document is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement of meeting resolutions and approvals, not the full Annual Report (10-K) or other detailed reports themselves.
2025-04-22 Chinese
第六届董事会第四十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 40th meeting of the 6th Board of Directors of Beijing Xinghao Pharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to various reports and announcements that are disclosed elsewhere (e.g., annual report, financial report, remuneration plans, audit reports). The document primarily focuses on board meeting decisions and changes, including election of directors and amendments to company bylaws. It does not contain the full text of financial reports or other detailed filings but rather the board's resolutions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related board meeting resolutions.
2025-04-22 Chinese
独立董事候选人声明与承诺（徐辉）
Board/Management Information Classification · 100% confidence The document is a declaration and commitment statement by an independent director candidate (徐辉) for Beijing Xinghao Pharmaceutical Co., Ltd. It contains detailed qualifications, legal compliance, and independence criteria for the candidate. There are no financial statements, earnings data, or report summaries. The document is a formal announcement related to board/management information, specifically about a director candidate's declaration and commitment. It is not an annual report, audit report, or any financial report. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 2734 characters, which is consistent with a detailed announcement rather than a full report.
2025-04-22 Chinese
董事换届公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the change in the company's board of directors, detailing nominations, qualifications, and approvals related to the board re-election. It includes information about the nomination committee's opinions and confirms compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The document is clearly about board/management changes, fitting the category of Board/Management Information (MANG). The document length is short and focused solely on board changes, not an annual report or other filings.
2025-04-22 Chinese
2024年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金存放与实际使用情况的专项报告" which translates to a "Special Report on the Storage and Actual Use of Raised Funds." It details the issuance of shares, the amount of funds raised, the storage of these funds, their actual usage, changes in fund usage, and compliance with regulatory requirements. It includes detailed financial figures related to fundraising, usage, and investment of idle funds, as well as audit and sponsor verification opinions. The document is a specialized report focusing on the management and use of capital raised through a public stock issuance, rather than a general financial report or earnings release. This fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (9562 characters) and detailed financial data confirm it is a substantive report, not merely an announcement or certification. Therefore, the appropriate classification is CAP.
2025-04-22 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.